Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating
/ administration & dosage
Antineoplastic Agents, Immunological
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Apoptosis
/ drug effects
Apoptosis Regulatory Proteins
/ metabolism
Bendamustine Hydrochloride
/ administration & dosage
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Immunoglobulin Heavy Chains
/ genetics
Immunoglobulin Variable Region
/ genetics
Leukemia, Lymphocytic, Chronic, B-Cell
/ blood
Leukocytes, Mononuclear
Male
Middle Aged
Mutation
Primary Cell Culture
Proto-Oncogene Proteins
/ metabolism
Rituximab
/ administration & dosage
Tumor Cells, Cultured
Young Adult
bcl-2-Associated X Protein
/ metabolism
Bendamustine
IGVH mutational status
chronic lymphocytic leukemia
gene expression profile
protein expression
rituximab
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
7
9
2018
medline:
21
7
2020
entrez:
7
9
2018
Statut:
ppublish
Résumé
We studied whether bendamustine (BENDA) alone or with rituximab (RIT) modifies
Identifiants
pubmed: 30187811
doi: 10.1080/10428194.2018.1493730
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Antineoplastic Agents, Immunological
0
Apoptosis Regulatory Proteins
0
BAX protein, human
0
BBC3 protein, human
0
Immunoglobulin Heavy Chains
0
Immunoglobulin Variable Region
0
Proto-Oncogene Proteins
0
bcl-2-Associated X Protein
0
Rituximab
4F4X42SYQ6
Bendamustine Hydrochloride
981Y8SX18M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM